iSTAR Medical announces outstanding results with MIGS implant

Two-year final results from STAR-I trial and initial data from STAR-II European trial tout MINIjectTM as a highly promising treatment.

Wavre, Belgium: 29 April 2020 – iSTAR Medical SA, a clinical-stage medical device company pioneering truly biocompatible solutions for glaucoma, today announced positive results from two clinical trials of its micro-invasive glaucoma surgery (MIGS) implant MINIjectTM. Both studies showed consistently outstanding reduction of intraocular pressure (IOP) and reduced need for IOP-lowering medication in over 50 patients with open angle glaucoma, following standalone MINIject implantation. Two-year final outcomes from iSTAR Medical’s STAR-I trial and six-month results from its European trial STAR-II have been accepted for presentation at the European Glaucoma Society (EGS) meeting, now postponed to December 2020 following the Covid-19 pandemic.

More info on iSTAR Medical‘s website.